[ad_1]
India temporarily banned the Indian Serum Institute, which produces Oxford / AstraZeneca’s new type of corona virus (Covid-19) vaccine, which it has approved for use, from exporting vaccines to other countries and selling vaccines through the private sector.
The company’s senior manager, Adar Poonawalla, told the AP that the government approved the use of the vaccine, “on the condition that no exports take place until we are sure that vulnerable communities in India are protected.”
On the other hand, Poonawalla pointed out that the vaccine was also banned from the market and said that “we can only give vaccines to the Indian government at the moment.”
The restriction on the company, the world’s largest vaccine maker, could delay delivery of vaccines to developing countries.
The Serum Institute of India planned to produce 1 billion doses of vaccines for countries in need under the Covid-19 Vaccine Global Access Program (COVAX) led by the World Health Organization (WHO).
Poonawalla noted that the company has signed a contract to produce 100 million doses of the Oxford / AstraZeneca vaccine to deliver to COVAX and the vaccine developed by the American company Novavax, which has not yet been approved, and that they are negotiating to produce from 300 to 400 million doses in addition to the contract. He stated that it is planned to provide 200 to 300 million doses of vaccine to COVAX by the end of the year.
Due to the export ban, it may be spring for the first vaccines to arrive in these countries.
DO MUTATION VACCINES AFFECT?
